Price
$4.735
Increased by +0.96%
Dollar Volume (20D)
346.8 K
ADR%
4.43
Earnings Report Date (estimate)
May 7, 24
Shares Float
32.44 M
Shares Outstanding
34.25 M
Shares Short
713.28 K
Market Cap.
160.3 M
Beta
1.28
Price / Earnings
N/A
20D Range
4.2 4.8
50D Range
3.83 4.81
200D Range
3.03 5.98
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 23 -0.34
Increased by +74.81%
-0.38
Increased by +10.53%
Aug 14, 23 -0.43
Increased by +60.19%
-0.42
Decreased by -2.38%
May 9, 23 -0.5
Increased by +37.5%
-0.69
Increased by +27.54%
Mar 16, 23 -0.83
Decreased by -9.21%
-0.83
Nov 14, 22 -1.35
Decreased by -90.14%
-1.13
Decreased by -19.47%
Aug 11, 22 -1.08
Increased by +29.41%
-0.83
Decreased by -30.12%
May 12, 22 -0.8
Increased by +38.46%
-0.81
Increased by +1.23%
Mar 10, 22 -0.76
Increased by +31.53%
-0.69
Decreased by -10.14%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0
Decreased by N/A%
-7.11 M
Increased by +47.57%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0
Decreased by N/A%
-8.24 M
Increased by +24.22%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0
Decreased by N/A%
-9.56 M
Decreased by -20.77%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0
Decreased by N/A%
-10.99 M
Decreased by -53.68%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0
Decreased by N/A%
-13.56 M
Decreased by -102.63%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0
Decreased by N/A%
-10.87 M
Increased by +3.88%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0
Decreased by N/A%
-7.92 M
Increased by +0.99%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0
Decreased by N/A%
-7.15 M
Decreased by -51.38%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.